title: Update on Gastrointestinal Stromal Tumors for Radiologists.
abstract: The management of gastrointestinal stromal tumors (GISTs) has evolved significantly in the last two decades due to better understanding of their biologic behavior as well as development of molecular targeted therapies. GISTs with exon 11 mutation respond to imatinib whereas GISTs with exon 9 or succinate dehydrogenase subunit mutations do not. Risk stratification models have enabled stratifying GISTs according to risk of recurrence and choosing patients who may benefit from adjuvant therapy. Assessing response to targeted therapies in GIST using conventional response criteria has several potential pitfalls leading to search for alternate response criteria based on changes in tumor attenuation, volume, metabolic and functional parameters. Surveillance of patients with GIST in the adjuvant setting is important for timely detection of recurrences.
authors.affiliation: Department of Imaging, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Radiology, Brigham and Women's Hospital, Boston, MA 02115, USA.
authors.forename: Sree Harsha
authors.initials: SH
authors.lastname: Tirumani
authors.affiliation: Department of Radiology, Tata Memorial Centre, Mumbai 400012, India.
authors.forename: Akshay D
authors.initials: AD
authors.lastname: Baheti
authors.affiliation: Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
authors.forename: Harika
authors.initials: H
authors.lastname: Tirumani
authors.affiliation: Department of Imaging, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Radiology, Brigham and Women's Hospital, Boston, MA 02115, USA.
authors.forename: Ailbhe
authors.initials: A
authors.lastname: O'Neill
authors.affiliation: Department of Imaging, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Radiology, Brigham and Women's Hospital, Boston, MA 02115, USA.
authors.forename: Jyothi P
authors.initials: JP
authors.lastname: Jagannathan
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005091:Exons; D005770:Gastrointestinal Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000235:genetics; D046152:Gastrointestinal Stromal Tumors / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use; D009154:Mutation; D009364:Neoplasm Recurrence, Local; D011743:Pyrimidines / Q000627:therapeutic use; D013385:Succinate Dehydrogenase / Q000235:genetics; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D011743:Pyrimidines; C491545:SDHD protein, human; D000068877:Imatinib Mesylate; D013385:Succinate Dehydrogenase
keywords: Choi criteria; Gastrointestinal stromal tumor; Imatinib; Risk stratification